The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Edwards Lifesciences Corporation(EW) Shareholders

Core Insights - The Gross Law Firm has issued a notice to shareholders of Edwards Lifesciences Corporation regarding a potential class action lawsuit related to misleading statements about the company's revenue expectations for fiscal year 2024 [1][2]. Group 1: Allegations and Financial Impact - The allegations state that Edwards Lifesciences provided investors with misleading information about the expected revenue growth of its core product, Transcatheter Aortic Valve Replacement (TAVR), during the class period from February 6, 2024, to July 24, 2024 [2]. - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024 and significantly reduced its revenue guidance for the TAVR platform for the full fiscal year 2024, attributing the decline to increased pressure on hospital workflows from the growth of other structural heart therapies [2]. - Following the announcement, Edwards' stock price plummeted from $86.95 per share on July 24, 2024, to $59.70 per share on July 25, 2024, marking a decline of approximately 31.34% in just one day [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline set for December 13, 2024, to seek lead plaintiff status [3]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates throughout the case lifecycle [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceitful practices and misleading statements by companies [4].